Literature DB >> 12546570

The Zenith aortic stent-graft: a 5-year single-center experience.

Pierre Alric1, Robert J Hinchliffe, Shane T R MacSweeney, Peter W Wenham, Simon C Whitaker, Brian R Hopkinson.   

Abstract

PURPOSE: To evaluate the efficacy and midterm results of the Zenith stent-graft in the treatment of abdominal aortic aneurysms (AAA).
METHODS: Since March 1994, 364 patients have undergone endovascular repair of infrarenal AAA. Of the 94 who were treated with the Zenith stent-graft from 1996 to 2002, 88 patients (82 men; mean age 72.6 +/- 6.5 years, range 47-88) with at least 6-month follow-up were analyzed. Sixty-one (69.3%) patients were considered at high risk for intervention; 7 ruptured AAAs were treated emergently. In all, 68 (77.3%) bifurcated stent-grafts (including 18 TriFab systems) and 20 aortomonoiliac configurations were used. Cumulative data on endoleak, migration, secondary procedures, and survival were evaluated with Kaplan-Meier analyses.
RESULTS: Implantation success was 97.7%; 2 (2.3%) access-related failures were converted to open repair (1 immediate, 1 at 3 months). There were 3 (3.4%) graft limb thromboses (2 immediate, 1 late), 3 (3.4%) cases of colon ischemia due to embolization in 1 and hypogastric artery occlusion in 2, and 1 (1.1%) renal infarction due to embolism. Three (3.4%) patients died within 30 days. Eleven (12.5%) endoleaks and 1 (1.1%) late endograft migration were recorded. The 5-year cumulative endoleak and migration rates were 15% and 7%, respectively. Sixty-three (71.6%) patients did not present any complication related to the repair during a mean follow-up of 20.6 +/- 14.9 months (range 6-68); notably, no complications were associated with the 18 TriFab systems. Six (6.8%) secondary procedures were performed (31% 5-year cumulative secondary procedural rate). All 6 (6.8%) aneurysm-related deaths (the 3 perioperative, 2 from late AAA rupture, and 1 during a secondary procedure) and 14 of 18 (20.4%) non-aneurysm-related deaths occurred in high-risk patients; the 5-year cumulative survival rates were 57% for any death and 92% for aneurysm-related deaths.
CONCLUSIONS: The Zenith stent-graft appears both safe and effective in terms of midterm outcome of endovascular aortic aneurysm repair.

Entities:  

Mesh:

Year:  2002        PMID: 12546570     DOI: 10.1177/152660280200900602

Source DB:  PubMed          Journal:  J Endovasc Ther        ISSN: 1526-6028            Impact factor:   3.487


  4 in total

1.  Clinical significance of endoleaks characterized by computed tomography during aortography performed immediately after endovascular abdominal aortic aneurysm repair: prediction of persistent endoleak.

Authors:  Motoki Nakai; Hirotatsu Sato; Morio Sato; Yuko Tanba; Yasutaka Noda; Akira Ikoma; Hiroki Sanda; Kohei Nakata; Hiroki Minamiguchi; Nobuyuki Kawai; Tetsuo Sonomura; Kazushi Kishi; Yosiharu Nishimura; Yoshitaka Okamura
Journal:  Jpn J Radiol       Date:  2012-10-10       Impact factor: 2.374

2.  Comparison of Endovascular Stent Grafts for Abdominal Aortic Aneurysm Repair in Medicare Beneficiaries.

Authors:  Dominique B Buck; Peter A Soden; Sarah E Deery; Sara L Zettervall; Klaas H J Ultee; Bruce E Landon; A James O'Malley; Marc L Schermerhorn
Journal:  Ann Vasc Surg       Date:  2017-09-08       Impact factor: 1.466

Review 3.  Risk factors for ischaemic colitis after surgery for abdominal aortic aneurysm: a systematic review and observational meta-analysis.

Authors:  Matthew J Lee; Sarah L Daniels; Thomas M Drake; Ian J Adam
Journal:  Int J Colorectal Dis       Date:  2016-06-01       Impact factor: 2.571

4.  Long-term outcomes of endovascular aortic aneurysm repair with the Zenith AAA endovascular graft: a single-center study.

Authors:  Hiroshi Kawamata; Hiroyuki Tajima; Tatsuo Ueda; Hidemasa Saito; Daisuke Yasui; Tadashi Kaneshiro; Naoko Takenoshita; Shouhei Mizushima; Takahiko Mine; Jiro Kurita; Yosuke Ishii; Tetsuro Morota; Takashi Nitta; Yuji Maruyama; Hajime Imura; Dai Nishina; Masahiro Fujii; Ryuzo Bessho
Journal:  Jpn J Radiol       Date:  2019-10-29       Impact factor: 2.374

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.